







CHERRY BIOTECH

Cubix Platform: Mimic Human tissues for drug test Organ on Chip Technologie An Alternative to animal testing

contact@cherrybiotech.com - +33(0) 987 047 035 - All rights reserved. Reproduction in whole or in part without written permission is prohibited



CONVENTIONAL PRECLINICAL MODELS: BOTTLENECK IN DRUG DISCOVERY



contact@cherrybiotech.com - +33(0) 987 047 035 - All rights reserved. Reproduction in whole or in part without written permission is prohibited



SOLUTION: HOW DOES OUR ORGAN ON CHIP WORK?

DEV recipes for food



DEV protocols for tissue culture



Liver model

- **Reconstruct** 3D tissues (Physio or Pathologic) ۲
- Vascularize any tissues ۰
- **Interconnect organs** : metastases, Immune cells, etc
- Data : Microscope and Omics interoperability

Our specific Patented technology: Convert Standard Multiwell



contact@cherrybiotech.com - +33(0) 987 047 035 -

3 All rights reserved. Reproduction in whole or in part without written permission is prohibited



WHY NOW ? NEW REGULATION AND IMPACTS



Ewart et al, 2021, Qualifying a human Liver-Chip for predictive toxicology: Performance assessment and economic implications

contact@cherrybiotech.com - +33(0) 987 047 035 - All rights reserved. Reproduction in whole or in part without written permission is prohibited 4



IN VITRO TOX MKT & EARLY GO TO MARKET









+4800 Pharma & Biotech Companies

+1100 Contract Research Organizations





+8000 Academics Labs including hospitals (Personalised Medicine)



contact@cherrybiotech.com - +33(0) 987 047 035 -All rights reserved. Reproduction in whole or in part without written permission is prohibited



CUBIX platform : 1 to 4 modules

€120K

Annual Recurring revenue :

€40K/control unit (200/year)

contact@cherrybiotech.com - +33(0) 987 047 035 -All rights reserved. Reproduction in whole or in part without written permission is prohibited



TEAM (16 people) & ACHIEVEMENTS



Jeremy Cramer, PhD **Executive President & Founder**



Alexis Peyroles CEO Former listed Biotech CEO



Antoni Corbera, PhD СТО Patent Microfluidic Multiwell adaptor





Dario Fassini, PhD **Biological Model** Patent extracellular







1st Product commercialized: **CHERRY TEMP**



Since 2014



Giulia Antonioli Finance & Admin Analytics comptability



Pierre Gaudriault, PhD **Business Dev** Contract NovoNordisk





(co-founders)

Board Members



Mael le Berre, Phd CEO @BforCure Founder of BForCure & 4DCell Medical device expetise (PCR)



5 Patents

Cubix Pilots

8 Beta Platforms

Total Non dilutive FUNDS

€12m





NEXT STEP: FINANCING EARLY GO TO MARKET



Kick start the commercialization of our Microfluidic Mutliwell



TIMING

2023 BRIDGE FUNDING



Biological Model catalogue expansion

Secure production capabilities of 100 CUBIX

2024 **Serie A**



contact@cherrybiotech.com - +33(0) 987 047 035 -All rights reserved. Reproduction in whole or in part without written permission is prohibited

CHERRY

Contact information: jeremy.cramer@cherrybiotech.com – President alexis.peyroles@cherrybiotech.com – CEO www.cherrybiotech.com



USP: CONVERT PHARMA STANDARD IN ORGAN ON CHIP

	СНЕРКЧ 🕜 ВЮТЕСН	MIMETRS Ihe organiania-chip company		DRAPER		🛞 emulate
PDMS free	ОК	ОК	ОК	ОК	NOT	NOT
Standard format	ОК	ОК	NOT	ОК	NOT	NOT
Physiological Flow (Shear Stress)	ОК	NOT	ОК	ОК	ОК	ОК
Incubator free	ОК	ОК	ОК	ОК	ОК	NOT
RT Live Imaging	ОК	ОК	NOT	ОК	ОК	NOT
Convert Standard Multiwell	ОК	NOT	NOT	NOT	NOT	NOT



"The uniqueness of the CUBIX is that it is **compatible with a standard** 24-well tissue culture plates, making it easily applicable to **medium-scale production**. The use of CUBIX may well become a "**must**" for all Novo Nordisk's preclinical trials."

Karin Conde-Knape, Senior Vice President Novo Nordisk